Live Breaking News & Updates on First line treatment of patients with medium to high risk unresectable or metastatic rcc

Stay updated with breaking news from First line treatment of patients with medium to high risk unresectable or metastatic rcc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

China , Peking , Beijing , Jun-guo , National-medical-products-administration-of-china , Shanghai-junshi-biosciences-co-ltd , University-cancer-hospital , International-metastatic-renal-cell-carcinoma-database-consortium , National-medical-products-administration , Peking-university-cancer-hospital , News , Global-oncology